Open, Long-Term Safety Study With Vildagliptin in Patients With Type 2 Diabetes (as add-on therapy with metformin, thiazolidinedione, alpha-glucosidase inhibitor or rapid-acting insulin secretagogues)
Phase 3
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-jRCT2080221153
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 216
Inclusion Criteria
Patients with type 2 diabetes inadequately controlled with diet, exercise and metformin, thiazolidinedione, or alpha-GI, or glinides monotherapy
- Age in the 20 years or over inclusive
- HbA1c in the range of >= 6.5 to =< 10%
Exclusion Criteria
- Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- Significant heart diseases
- Significant diabetic complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method